Entering text into the input field will update the search result below

Oramed submits phase 2a protocol to FDA for diabetes treatment, +14%

Feb. 10, 2014 3:29 PM ETOramed Pharmaceuticals Inc. (ORMP) StockBy: Carl Surran, SA News Editor
  • Oramed Pharmaceuticals (NASDAQ:ORMP +13.9%) says it delivered to the FDA the protocol for phase 2a testing of its oral insulin capsule treating both Type 1 and Type 2 diabetes.
  • The protocol was submitted under ORMP's existing investigational new drug application for its ORMD-0801 drug candidate; the double-blind, placebo controlled study, expected to start next month, will be carried out over seven days at an in-patient facility with 24 Type 1 diabetic patients.

Recommended For You

More Trending News

About ORMP Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ORMP--
Oramed Pharmaceuticals Inc.